- Open Access
Rasch analysis of the Multiple Sclerosis Impact Scale (MSIS-29)
© Ramp et al; licensee BioMed Central Ltd. 2009
- Received: 21 December 2008
- Accepted: 22 June 2009
- Published: 22 June 2009
Multiple Sclerosis (MS) is a degenerative neurological disease that causes impairments, including spasticity, pain, fatigue, and bladder dysfunction, which negatively impact on quality of life. The Multiple Sclerosis Impact Scale (MSIS-29) is a disease-specific health-related quality of life (HRQoL) instrument, developed using the patient's perspective on disease impact. It consists of two subscales assessing the physical (MSIS-29-PHYS) and psychological (MSIS-29-PSYCH) impact of MS. Although previous studies have found support for the psychometric properties of the MSIS-29 using traditional methods of scale evaluation, the scale has not been subjected to a detailed Rasch analysis. Therefore, the objective of this study was to use Rasch analysis to assess the internal validity of the scale, and its response format, item fit, targeting, internal consistency and dimensionality.
Ninety-two persons with definite MS residing in the community were recruited from a tertiary hospital database. Patients completed the MSIS-29 as part of a larger study. Rasch analysis was undertaken to assess the psychometric properties of the MSIS-29.
Rasch analysis showed overall support for the psychometric properties of the two MSIS-29 subscales, however it was necessary to reduce the response format of the MSIS-29-PHYS to a 3-point response scale. Both subscales were unidimensional, had good internal consistency, and were free from item bias for sex and age. Dimensionality testing indicated it was not appropriate to combine the two subscales to form a total MSIS score.
In this first study to use Rasch analysis to fully assess the psychometric properties of the MSIS-29 support was found for the two subscales but not for the use of the total scale. Further use of Rasch analysis on the MSIS-29 in larger and broader samples is recommended to confirm these findings.
- Multiple Sclerosis
- Differential Item Functioning
- Expand Disability Status Scale
- Classical Test Theory
- Partial Credit Model
Multiple Sclerosis (MS) is a chronic and degenerative neurological disease affecting an estimated 2.5 million people worldwide . MS causes a number of impairments such as motor weakness, spasticity and incoordination, pain, fatigue, blurred vision, sensory dysasthesias, depression, anxiety, and bladder dysfunction. These have a significant impact on a person's daily living activities (function), participation and quality of life (QoL) [2–7]. QoL and changes following treatment in persons with MS are difficult to measure despite recent advances in MS treatments (medications), and support for adjuvant and supportive interventions such as rehabilitation [8, 9].
A number of measurement scales, both generic and disease specific, have been used to assess the quality of life and functioning of patients with MS. These include the Kurtzke Expanded Disability Status Scale (EDSS) , Multiple Sclerosis Quality of Life (MSQOL-54) , the Multiple Sclerosis Quality of Life Inventory (MSQLI) , the Functional Assessment of Multiple Sclerosis (FAMS) , the Multiple Sclerosis Functional Composite (MSFC) , the UK Neurological Disability Scale (UKNDS) , the Health-Related Quality of Life Questionnaire for Multiple Sclerosis (HRQOL-MS)  and the Medical Outcomes 36-item Short-Form Health Survey (SF-36) .
One scale that is increasingly being used in both research and clinical settings is the Multiple Sclerosis Impact Scale (MSIS-29) . This scale was developed as a disease-specific measure of HRQoL using the patient's perspective on disease impact in MS. It was designed to be a scientifically rigorous, clinically useful, disease specific instrument to enhance existing measures used in treatment trials, developed from and completed by patients with MS, ensuring measurement of HRQoL outcomes relevant to those patients that are sometimes overlooked by clinicians [2, 19]. The scale's authors engaged standard psychometric techniques of classical test theory (CTT) to construct the MSIS-29, on a United Kingdom community sample with MS . Using factor analysis, they identified two dimensions that mirrored previous findings of patients' views of health status, which they labelled physical impact and psychological impact . The physical impact dimension (MSIS-29-PHYS: consisting of 20 items) and the psychological impact dimension (MSIS-29-PSYCH: consisting of nine items) measure related, but distinct, constructs (correlatingr r = 0.62), yielding two separate scale scores, with higher scores indicating higher impact level . Although a total impact score can be calculated, the authors do not recommend its use in clinical trials or epidemiological research, as combining the subscales conceals possible diverging effects of treatment on the two health dimensions .
A number of studies have re-examined the psychometric properties of the MSIS-29 using CTT methods [19–25]. Each study has shown overall support for the original findings on the MSIS-29 physical and psychological scale's data quality, scaling assumptions, acceptability, reliability, external validity and responsiveness to change in various settings and in a number of MS populations in the UK [19, 21, 24], Ireland [20, 23], the Netherlands [22, 26] and, more recently, Iran . None of these subsequent studies, however, re-examined the internal factor structure of the MSIS-29 or its subscales.
As with all new scales, the MSIS-29 requires further validation in a variety of settings and samples, and utilizing different methodologies [18, 19, 21]. In particular the scale authors suggest that the MSIS-29 should be subjected to validation with newer psychometric methods such as Rasch analysis [18, 19, 21]. Rasch analysis, which was originally developed by Danish mathematician Georg Rasch , is increasingly being used in the development and evaluation of clinical tools for the health and medical sciences . Rasch analysis provides the opportunity to evaluate many aspects of a scale's functioning, including a detailed assessment of response format, item content, response bias, dimensionality and appropriate targeting of a scale [29–31]. It also allows the transformation of ordinal level scale scores into equal interval measurement, which is particularly important when measuring change or responsiveness to treatment [28, 29]. Only scales that fit the Rasch model fulfil the requirements of objective conjoint measurement required for mathematical manipulation of the scores.
To date, no study has made full use of the features available in Rasch analysis to investigate the internal validity of the MSIS-29. Two previous studies used Rasch analysis to assess specific issues that arose in the course of their research [23, 26]. In addition to a study conducted in the Netherlands , an Irish study showed support for the MSIS-29 physical subscale's divergent validity using Rasch calibrated interval level scale scores .
With the increasing use of the MSIS-29 in research in many parts of the world further analysis of the scale's psychometric properties needs to be undertaken. The aim of this study was to use Rasch analysis to further test the internal validity of the MSIS-29 subscales (MSIS-29-PHYS, MSIS-29-PSYCH) and total scale (MSIS-29-TOTAL) in terms of response format, item fit, model fit, item bias, targeting, internal consistency and dimensionality in an Australian sample.
Participants and setting
This study involves secondary analysis of data collected for a larger study conducted in Melbourne, Australia evaluating the efficacy of rehabilitation in multiple sclerosis patients . Ethics approval for this study was granted by the Royal Melbourne Hospital (RMH) Human Research and Ethics Committees. A community sample of persons aged between 18–65 years with 'definite' MS (McDonald criteria ) were recruited using the RMH MS Database . Of the 101 eligible patients who consented to the broader study, 92 patients [66 (72%) women; 26 (28%) men] were included in the current cross-sectional study, having completed the MSIS-29 at baseline. These participants ranged in age from 29 to 65 years with a mean age of 50.45 years (SD = 8.96 years). Years since diagnosis ranged from 1 to 43 years (M = 10.56, SD = 7.40) with 30% (N = 26) classified as Relapsing/remitting, 58% (N = 53) as Secondary Progressive and the remainder (11, 12%) as Primary Progressive. Twenty percent (N = 18) recorded Expanded Disability Status Scale (EDSS)  scores between 0 and 3, 58% (N = 53) scored between 3.5 and 6.0 and 23% (N = 21) scored 6.5 and above.
Procedure & materials
As part of the larger study  participants were asked to complete a questionnaire booklet which included the MSIS-29 . The MSIS-29 is a 29 item scale consisting of two subscales, a 20-item scale measuring physical impact (MSIS-29-PHYS) and a 9-item scale measuring psychological impact (MSIS-29-PSYCH) . All items have a polytomous response format (range 1–5), with higher scores indicating higher impact level. A total score for each subscale can be derived by summing items and transforming them into a score out of 100. The authors suggest a total scale score can also be calculated (MSIS-29-TOTAL), however they advise caution against its use in clinical trials and epidemiological studies. The MSIS-29 has been shown to have good internal consistency, with Cronbach's alpha values for each of the subscales of between 0.87 and 0.96 [18, 19, 21, 23]. A number of studies have shown overall support for the convergent and discriminant construct validity of the MSIS-29-PHYS and MSIS-29-PSYCH [19, 20, 22].
Separate Rasch analyses were conducted to assess the internal validity of the MSIS-29-PHYS, MSIS-29-PSYCH and MSIS-29-TOTAL using RUMM2020 software . Each set of items was assessed for threshold ordering, overall model fit, item fit, person fit, reliability, differential item functioning, targeting and dimensionality. The procedures adopted were consistent with the published guidelines of Tennant and colleagues [34, 31].
Before conducting Rasch analyses a decision needs to be made as to whether the rating scale model or the partial credit model should be used to analyse the scales . The partial credit model, unlike the rating scale model, does not require assumptions to be met regarding item distribution . It allows items to have different numbers of response categories , and does not assume the distance between response thresholds is uniform for all items . RUMM2020 provides the likelihood ratio test to identify the form of Rasch model that is most appropriate for a given set of data. A significant likelihood ratio test indicates that the distance between response thresholds is inconsistent, and therefore, a partial credit model is preferred .
For a scale to have good fit to the Rasch model it is expected that patients with high levels of the measured attribute (e.g. physical or psychological impact of MS), will consistently endorse high scoring response options across all items and patients with low levels will endorse low scoring responses. All items are expected to have ordered response thresholds, with the term threshold signifying the point between adjacent response categories where either response is equally probable. Disordered thresholds occur when respondents inconsistently endorse response categories. This can be the result of ambiguous response labelling or too many response options. The presence of disordered thresholds can be detected from the threshold map provided by RUMM2020, and the extent of the disordering determined by inspection of the category probability curves for each item . Disordered thresholds can be resolved, where considered necessary, by collapsing adjacent response categories.
Model fit was assessed using three summary statistics. Good overall model fit was indicated by a non-significant item-trait interaction chi-square probability value, indicating the hierarchical ordering of items is consistent over all levels of the trait. Item and person fit are indicated by two item-person interaction fit residuals transformed to approximate z-scores, with a mean of zero and standard deviation of one indicating perfect fit to the model. Residuals and chi-square probability values of individual items or persons were inspected, with misfit indicated by fit residual values > ± 2.5 and/or chi-square probability values < 0.05 (using a Bonferonni adjustment to the alpha level for the number of items) . High positive fit residual values indicate misfit to the model and high negative fit residuals indicate redundancy. Internal consistency of the scale was estimated by the Person Separation Index (PSI), which is interpreted in the same way as a Cronbach's alpha coefficient, with values above 0.7 considered acceptable [30, 31].
Differential item functioning (DIF) was assessed to examine potential item bias caused by different groups (gender, age groups) in the sample. An analysis of variance is conducted for each item to examine scores over different levels of the person factor, and over different levels of the underlying trait (using a Bonferroni adjusted alpha level) . The current study assessed potential DIF on sex and age group (< 53 years/≥ 53 years).
To assess the ability of the scales to appropriately target the population being measured, person-item threshold distribution maps were inspected. A well targeted scale should include a set of items that span the full range of person estimates.
Possible response dependency among the items was investigated by inspecting the residual correlation matrix  for pairs of items with correlations exceeding 0.3. Dimensionality of the scales was assessed using independent t-tests to compare person estimates derived from the two most disparate subsets of scale items . These subsets of items are defined by positive and negative loadings on the first factor extracted using a principal component analysis of residuals. For a scale to be considered unidimensional no more than five percent of cases should show a significant difference between their scores on the two subsets . If more than five percent show a difference a binomial test of proportions is used to calculate the 95% confidence interval around the t-test estimate. Unidimensionality is said to be supported if the value of five percent falls within the 95% confidence intervals [34, 36].
The sample size for Rasch analysis varies according to a number of parameters, including the degree of required precision of the person and item estimates, and the targeting of the sample. A well targeted sample is one in which the person distribution closely matches the item distribution when they are both calibrated on the same metric scale. A sample size of 64 cases is considered sufficient to give a stable item calibration within ± 0.5 logit where the sample is well targeted, rising to 144 when the sample is poorly targeted [33, 37].
Rasch calibrated person ability estimates for both subscales were imported into SPSS  from RUMM2020 and the correlation between the two subscales was assessed using a Spearman's correlation coefficient (rho).
Likelihood ratio tests for all three scales were significant, supporting the use of a partial credit Rasch model (MSIS-29-PHYS: p < 0.001; MSIS-29-PSYCH: p = 0.015; MSIS-29-TOTAL: p < 0.001).
MSIS-29 physical impact scale
The threshold map for the 20 items of the MSIS-29-PHYS indicated that over half (11/20) of the items had some degree of threshold disordering. A number of rescoring options were tested, however, a global rescore was found to be the most appropriate solution. All disordered thresholds were resolved by reducing the original 5-point response scale (12345) to a 3-point scale (01112), by merging the three middle response categories ('a little', 'moderately' and 'quite a bit').
Summary fit statistics for original and final models for MSIS-29 subscales
Item fit Mean
Person fit Mean
% significant t-tests
χ2 = 44.04, df = 20, p = .002
Rescoring to 3-point
χ2 = 21.59, df = 20, p = .36
Removal of 1 case
χ2 = 19.34, df = 20, p = .50
χ2 = 12.57,
df = 9, p = .18
Removal of 1 case
χ2 = 14.79,
df = 8, p = .10
Individual item fit statistics for the 20-item MSIS-29-PHYS
MSIS Item name
Do physically demanding tasks
Grip things tightly (e.g. turning on taps)
Problems with your balance
Difficulties moving about indoors
Heavy arms and/or legs
Tremor of your arms or legs
Spasms in your limbs
Your body not doing what you want it to do
Having to depend on others to do things for you
Limitations in your social and leisure activities at home
Being stuck at home more than you would like to be
Difficulties using your hands in everyday tasks
Having to cut down the amount of time you spent on work or other daily activities
Problems using transport (e.g. car, bus, train, taxi, etc.)
Taking longer to do things
Difficulty doing things spontaneously (e.g. going out on the spur of the moment)
Needing to go to the toilet urgently
No response dependency among the items was detected, with all correlations among the items in the residual correlation matrix falling below 0.3. Dimensionality of the rescored MSIS-29-PHYS was assessed using a Principal Component Analysis of the residuals to detect the two most disparate subsets of scale items, suggested by positive and negative loadings on the first component extracted. Results from a series of paired samples t-tests used to compare person estimates on the two most disparate subsets showed support for the unidimensionality of the MSIS-29-PHYS. Although seven of the 76 (9.21%) patients showed significantly different scores on the two subsets, the 95% confidence intervals around this estimate, derived from a binomial distribution, included five percent (CI: 4% to 14%), indicating that the unidimensionality of the scale was supported.
MSIS-29 psychological impact scale
The 9-item MSIS-29-PSYCH showed good fit to the Rasch model (p = 0.18) with good internal consistency (PSI = .90) (see Analysis 4 – Table 1). The threshold map showed disordered thresholds for three items (items 21, 22 & 26). As the level of disorder revealed in the category probability curves for these items was relatively minor and model fit was satisfactory, the original 5-point response format was retained.
Individual item fit statistics for the nine-item MSIS-29-PSYCH
MSIS Item name
Feeling mentally fatigued
Worries related to your MS
Feeling anxious or tense
Feeling irritable, impatient, or short tempered
Lack of confidence
MSIS-29 total scale
The MSIS-29-TOTAL was then subjected to Rasch analysis. Item thresholds of all 29 items were checked for disordering. As a large proportion of items (18 of the 29 items) were found to have some level of disordering, a global rescore of items was performed to resolve this problem. Collapsing the original 5-point scale (12345) into a 3-point scale (01112) resolved all disordering.
To establish whether the total scale represents a single underlying construct the dimensionality of the total rescored MSIS-29-TOTAL was examined, prior to generating model fit statistics. Independent t-tests comparing scores from the two most disparate subsets of items failed to find support for the unidimensionality of the total scale with 11 out of 71 t-tests showing a significant difference (15.49%, 95% CI: 10%, 21%). As expected, the items representing the MSIS-29-PHYS and MSIS-29-PSYCH separated into different factors. These results indicate that it is not appropriate to combine the physical and psychological items of the MSIS-29 to produce a total scale score. As unidimensionality is an essential requirement for Rasch analysis no further analyses were conducted on the combined set of items.
Spearman correlation coefficients were calculated from Rasch derived person estimates to assess the intercorrelation between the MSIS-29-PHYS and MSIS-29-PSYCH. There was a relatively strong correlation (rho = 0.62) between these two scales, consistent with Hobart and colleagues' original finding that they measure similar but distinct constructs .
Although previous studies using classical theory based techniques have found support for the psychometric properties of the MSIS-29, this is the first study to systematically assess all aspects of the scale using Rasch analysis. Overall support was established for the psychometric properties of the individual scales of the MSIS-29 (MSIS-29-PHYS, MSIS-29-PSYCH) with adequate fit to the Rasch model, no differential item bias, good internal consistency and support for both the targeting and unidimensionality of the scales. A number of issues emerged however in relation to the response format of items, and the fit of some items. The results also suggest that it is not appropriate to combine the two subscales to form a total MSIS score.
Inspection of the item response format for the MSIS-29-PHYS, MSIS-29-PSYCH and MSIS-29-TOTAL revealed issues regarding the ordering of response categories. Substantial disordering of thresholds was identified for many of the MSIS-29-PHYS items, and minor disordering was identified for some of the MSIS-29-PSYCH items. A reduction in number of response categories, from five to three, for the MSIS-29-PHYS items resolved any disordering. No rescoring was undertaken for the MSIS-29-PSYCH items due to the relatively minor degree of disordering.
Problems with the response format in this study may be influenced by the relatively small sample used in this study and will need to be verified in larger and broader samples before specific recommendations can be made. It does however suggest that some modifications to the response format used in this test may be warranted in future studies to reduce potential confusion for respondents. These results suggest that they are unable to reliably distinguish between what is meant by the terms 'a little', 'moderately' and 'quite a bit'; which could be replaced by a single category (e.g. moderately). Despite the reduction in response options from five to three the revised MSIS-29-PHYS scale showed good internal consistency (PSI = .93), supporting this revision.
The rescored MSIS-29-PHYS and MSIS-29-PSYCH scales each revealed a misfitting item (item 20: needing to go to the toilet urgently; and item 22: problems sleeping, respectively). Given the non-significant Bonferroni adjusted p-values for each item, and that good fit to the Rasch model for each scale was achieved, these items were retained.
The Rasch assumption of unidimensionality was supported for both the rescored MSIS-29-PHYS and MSIS-29-PSYCH. This finding replicated the original structure of the scale reported in earlier studies using factor analytic techniques of CTT . Unidimensionality was not satisfied for the MSIS-29-TOTAL, with results clearly showing that the two scales should not be combined to produce a total score. Consistent with previous research [18, 19, 22, 23], the current study showed that the two MSIS-29 scales measure related, but distinct constructs, as evidenced by an inter-correlation of rho = 0.62. The authors of the MSIS-29 were justified in their caution that a total scale score should not be used for clinical trials and epidemiological purposes .
Although controversy exists over the appropriateness of reducing human attributes to quantifiable scores , measurement of outcomes such as HRQoL can provide a more complete picture of disease burden. This is particularly pertinent for clinical trials of MS due to the disease's heterogeneous presentation, diverse symptoms and unpredictable path, as well as its high prevalence and the lack of a cure. This study provides further evidence for the internal validity of the physical and psychological impact scales of the MSIS-29, supporting their use in clinical and research settings as a measure of HRQoL to augment medical models of disease impact. This study also highlights the contribution that Rasch analysis can make in the evaluation of scales, over and above the classical test theory methods that have dominated the area of scale development in the health and social sciences.
The sample size of 92 MS patients was considered adequate for a Rasch analysis of the MSIS-29 , however future studies utilising larger samples should be undertaken using Rasch analysis to confirm the findings of this study. Broader samples, including a wider variety of patients with MS drawn from different settings, should also be utilized. Further evaluation of the response format of the scales should be undertaken to examine the decision made in this study to rescore the response categories of the MSIS-29-PHYS items. Ideally this would include the administration of the original and revised version of the MSIS scoring to the same people to compare their validity. Longitudinal studies should also be undertaken to assess the responsiveness of the MSIS-29 over time, using Rasch calibrated interval-scaled scores. For clinical studies evaluating the efficacy of various treatment and rehabilitation interventions it is important to accurately calculate change scores.
The MSIS-29 was designed as a disease-specific HRQoL instrument to augment existing measures for MS clinical trials. It was developed and evaluated using techniques based within classical test theory. The current study was the first to undertake a rigorous examination of the MSIS-29 scales' psychometric properties using Rasch analysis. Using an Australian MS sample this study found support for the internal validity, internal consistency reliability, targeting, and unidimensionality of the two MSIS-29 subscales. Modifications to the scoring format was necessary for the MSIS-29-PHYS, however, further validation of this is necessary before clinical implementation would be recommended. The summation of all items to form a total scale was not supported. The further use of Rasch analysis on the MSIS-29 in larger and broader samples is recommended to confirm the findings of the current study.
- Atlas: Country Resources for Neurological Disorders [http://www.who.int/mental_health/neurology/neurogy_atlas_lr.pdf]
- Mitchell AJ, Benito-Leon J, Gonzalez J-MM, Rivera-Navarro J: Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005,4(9):556–566. 10.1016/S1474-4422(05)70166-6View ArticlePubMedGoogle Scholar
- Keegan BM, Noseworthy JH: Multiple Sclerosis. Annu Rev Med 2002, 53: 285–302. 10.1146/annurev.med.53.082901.103909View ArticlePubMedGoogle Scholar
- Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson ME: Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001,15(3):247–258. 10.1191/026921501673658108View ArticlePubMedGoogle Scholar
- Khan F, McPhail T, Brand C, Turner-Stokes L, Kilpatrick T: Multiple sclerosis: disability profile and quality of life in an Australian community cohort. Int J Rehabil Res 2006,29(2):87–96. 10.1097/01.mrr.0000194393.56772.62View ArticlePubMedGoogle Scholar
- Khan F, Pallant J: Chronic pain in multiple sclerosis: prevalence, characteristics, and impact on quality of life in an Australian community cohort. J Pain 2007,8(8):614–623. 10.1016/j.jpain.2007.03.005View ArticlePubMedGoogle Scholar
- Khan F, Pallant J: Use of the International Classification of Functioning, Disability and Health (ICF) to identify preliminary comprehensive and brief core sets for multiple sclerosis. Disabil Rehabil 2007,29(3):205–213. 10.1080/09638280600756141View ArticlePubMedGoogle Scholar
- Khan F, Pallant J, Brand C, Kilpatrick T: Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomized controlled trial. J Neurol Neurosurg Psychiatry 2008,79(11):1230–5. 10.1136/jnnp.2007.133777View ArticlePubMedGoogle Scholar
- Khan F, Turner-Stokes L, Ng L, Kilpatrick T: Multidisciplinary rehabilitation for adults with multiple sclerosis (Review). Cochrane Database Syst Rev. 2007,18(2):CD006036.Google Scholar
- Kurtzke J: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33: 1444–1452.View ArticlePubMedGoogle Scholar
- Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW: A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995,4(3):187–206. 10.1007/BF02260859View ArticlePubMedGoogle Scholar
- LaRocca NG, Ritvo PG, Miller DM, Fischer JS, Andrews H, Paty DW: 'Quality of life' assessment in multiple sclerosis clinical trials: current status and strategies for improving multiple sclerosis clinical trial design. In Multiple sclerosis: advances in clinical trial design, treatment and future perspectives. Edited by: Goodkin DE, Rudick RA. London: Springer-Verlag; 1996:145–160.View ArticleGoogle Scholar
- Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang C, Lloyd S, Mo F, Stewart J, et al.: Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996, 47: 129–139.View ArticlePubMedGoogle Scholar
- Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fisher J, Lublin F, Miller A, Petkau J, Rao S, et al.: Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997,42(3):379–382. 10.1002/ana.410420318View ArticlePubMedGoogle Scholar
- Sharrack B, Hughes RA: The Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999, 5: 223–233.View ArticlePubMedGoogle Scholar
- Pfennings LE, Ploeg HM, Cohen L, Bramsen I, Polman CH, Lankhorst GJ, Vleugels L: A health-related quality of life questionnaire for multiple sclerosis patients. Acta Neurol Scand 1999,100(3):148–155.View ArticlePubMedGoogle Scholar
- Hobart J, Freeman J, Lamping D, Fitzpatrick R, Thompson A: The SF-36 in multiple sclerosis: why basic assumptions must be tested. J Neurol Neurosurg Psychiatry 2001,71(3):363–370. 10.1136/jnnp.71.3.363View ArticlePubMedGoogle Scholar
- Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A: The Multiple Sclerosis Impact Scale (MSIS-29) – A new patient-based outcome measure. Brain 2001, 124: 962–973. 10.1093/brain/124.5.962View ArticlePubMedGoogle Scholar
- Riazi A, Hobart J, Lamping D, Fitzpatrick R, Thompson A: Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples. J Neurol Neurosurg Psychiatry 2002,73(6):701–704. 10.1136/jnnp.73.6.701View ArticlePubMedGoogle Scholar
- Costelloe L, O'Rourke K, Kearney H, McGuigan C, Gribbin L, Duggan M, Daly L, Tubridy N, Hutchinson M: The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry 2007, 78: 841–844. 10.1136/jnnp.2006.105759View ArticlePubMedGoogle Scholar
- Riazi A, Hobart J, Lamping D, Fitzpatrick R, Thompson A: Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales. Mult Scler 2003, 9: 411–419. 10.1191/1352458503ms929oaView ArticlePubMedGoogle Scholar
- Hoogervorst E, Zwemmer J, Jelles B, Polman C, Uitdehaag B: Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability. Mult Scler 2004, 10: 569–574. 10.1191/1352458504ms1078oaView ArticlePubMedGoogle Scholar
- McGuigan C, Hutchinson M: The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure. J Neurol Neurosurg Psychiatry 2004,75(2):266–269.PubMedGoogle Scholar
- Hobart J, Riazi A, Lamping D, Fitzpatrick R, Thompson A: How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J Neurol Neurosurg Psychiatry 2005,76(11):1539–1543. 10.1136/jnnp.2005.064584View ArticlePubMedGoogle Scholar
- Ayatollahi P, Nafissi S, Eshraghian MR, Kaviani H, Tarazi A: Impact of depression and disability on quality of life in Iranian patients with multiple sclerosis. Mult Scler 2007, 13: 275–277. 10.1177/1352458506070960View ArticlePubMedGoogle Scholar
- van der Linden FAH, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BMJ: Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life. J Neurol Neurosurg Psychiatry 2006,77(10):1157–1162. 10.1136/jnnp.2006.090795View ArticlePubMedGoogle Scholar
- Rasch G: Probabilistic models for some intelligence and attainment tests. Volume Expanded edn. Chicago: The University of Chicago Press; 1960.Google Scholar
- Tennant A, McKenna SP, Hagell P: Application of Rasch Analysis in the Development and Application of Quality of Life Instruments. Value Health 2004, S22-S26. 10.1111/j.1524-4733.2004.7s106.xGoogle Scholar
- Bond TG, Fox CM: Applying the Rasch model: fundamental measurement in the human sciences. Mahwah, New Jersey: Lawrence Erlbaum Associates; 2001.Google Scholar
- DeVellis RF: Scale development: theory and applications. 2nd edition. Thousand Oaks, CA: Sage Publications; 2003.Google Scholar
- Pallant JF, Tennant A: An introduction to the Rasch measurement model: An example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 2007,46(1):1–18. 10.1348/014466506X96931View ArticlePubMedGoogle Scholar
- McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001,50(1):121–127. 10.1002/ana.1032View ArticlePubMedGoogle Scholar
- Andrich D, Lyne A, Sheridan B, Luo G: Rasch Unidimensional Measurement Models (RUMM2020 Version 4.0). Duncraig, Western Australia: Rumm Laboratory Pty Ltd; 2003.Google Scholar
- Tennant A, Conaghan PG: The Rasch Measurement Model in Rheumatology: What is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis Rheum 2007,57(8):1358–1362. 10.1002/art.23108View ArticlePubMedGoogle Scholar
- Smith EV: Detecting and evaluating the impact of multidimensionality using item fit statistics and principal component analysis of residuals. Journal of Applied Measurement 2002, 3: 205–231.PubMedGoogle Scholar
- Tennant A, Pallant J: Unidimensionality matters! (A tale of two Smiths?). Rasch Measurement Transactions 2006,20(1):1048–1051.Google Scholar
- Linacre JM: Sample size and item calibration stability. Rasch Measurement Transactions 1994,7(4):328.Google Scholar
- SPSS: SPSS Version 14.0. SPSS Inc; 2005.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.